Search Department of Consumer Protection Filtered Topic Search

Press Releases

DCP Press Release Header

08/28/2018

New Conditions Approved for Medical Marijuana Program

Tuesday, August 28th, 2018 – Today, the Regulations Review Committee of the General Assembly approved updated Medical Marijuana Program regulations that include the addition of 8 new conditions for adults, and 2 new conditions for patients under 18. Those conditions are:

 

For Adults:

 

  • Spasticity or Neuropathic Pain Associated with Fibromyalgia
  • Severe Rheumatoid Arthritis
  • Post Herpetic Neuralgia
  • Hydrocephalus with Intractable Headache
  • Intractable Headache Syndromes
  • Neuropathic Facial Pain

For Adults and Patients Under 18:

 

  • Muscular Dystrophy
  • Osteogenesis Imperfecta 

“Now that these regulations have been accepted, more patients with severe medical conditions will have access to medical marijuana as a treatment option,” said Consumer Protection Commissioner Michelle H. Seagull, “I want to thank our Board of Physicians and the committee for their thoughtful consideration of these conditions. I continue to be proud of the careful way that our program has expanded, and its commitment to a true medical model.”


The last step in this process is for DCP to submit the regulations to the Secretary of the State's Office, who will post the regulations online. At that point, the regulations will be final. Patient registration will be available within 24 hours of the regulations becoming final. DCP anticipates this process being complete within a week.  


There are currently 27,340 patients benefitting from the medical marijuana program, 953 certifying physicians, and now a total of 30 conditions approved for adults and 8 for patients under 18.

 

For more information about the medical marijuana program, please visit www.ct.gov/DCP/mmp.  Those with questions or concerns may email dcp.mmp@ct.gov.

 

###

Media Contact:
Lora Rae Anderson
lorarae.anderson@ct.gov
(860) 713-6019 (office)
(860) 247-8711 (cell)

Twitter: DCP on Twitter
Facebook: DCP on Facebook